

# Jay S Skyler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7725183/publications.pdf>

Version: 2024-02-01

268  
papers

18,850  
citations

13068

68  
h-index

13338

130  
g-index

287  
all docs

287  
docs citations

287  
times ranked

13762  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. <i>New England Journal of Medicine</i> , 2009, 361, 2143-2152.	13.9	900
2	Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. <i>Diabetes Care</i> , 2015, 38, 1964-1974.	4.3	690
3	Practical recommendations for the management of diabetes in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 546-550.	5.5	680
4	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Diabetes Care</i> , 2009, 32, 187-192.	4.3	624
5	Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes: The Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2005, 28, 1068-1076.	4.3	590
6	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 603-613.	13.9	584
7	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2011, 378, 412-419.	6.3	493
8	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017, 66, 241-255.	0.3	454
9	Validation of the insulin sensitivity index (ISI <sub>0,120</sub> ): comparison with other measures. <i>Diabetes Research and Clinical Practice</i> , 2000, 47, 177-184.	1.1	404
10	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Journal of the American College of Cardiology</i> , 2009, 53, 298-304.	1.2	373
11	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
12	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. <i>Lancet, The</i> , 2011, 378, 319-327.	6.3	325
13	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Circulation</i> , 2009, 119, 351-357.	1.6	308
14	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. <i>Lancet, The</i> , 2013, 381, 1905-1915.	6.3	301
15	Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. <i>Lancet, The</i> , 2001, 357, 331-335.	6.3	298
16	Fall in C-Peptide During First 2 Years From Diagnosis. <i>Diabetes</i> , 2012, 61, 2066-2073.	0.3	270
17	Use of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects: A 6-month, randomized, comparative trial. <i>Diabetes Care</i> , 2005, 28, 1630-1635.	4.3	265
18	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249

#	ARTICLE	IF	CITATIONS
19	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021, 44, 2589-2625.	4.3	244
20	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018, 41, 2560-2569.	4.3	239
21	Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial—Type 1. <i>Diabetes Care</i> , 2009, 32, 2269-2274.	4.3	224
22	Algorithms for Adjustment of Insulin Dosage by Patients Who Monitor Blood Glucose. <i>Diabetes Care</i> , 1981, 4, 311-318.	4.3	210
23	B-Lymphocyte Depletion With Rituximab and $\beta$ -Cell Function: Two-Year Results. <i>Diabetes Care</i> , 2014, 37, 453-459.	4.3	210
24	Suppression of Human Immunodeficiency Virus Type 1 Viral Load With Selenium Supplementation. <i>Archives of Internal Medicine</i> , 2007, 167, 148.	4.3	195
25	Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2001, 134, 203.	2.0	177
26	Diabetes Mellitus: Pathogenesis and Treatment Strategies. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4113-4117.	2.9	173
27	Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment. <i>Diabetes Care</i> , 2014, 37, 1069-1075.	4.3	168
28	Impaired Vibratory Perception and Diabetic Foot Ulceration. <i>Diabetic Medicine</i> , 1986, 3, 335-337.	1.2	167
29	Developmental and Behavioral Aspects of Diabetes Management in Youngsters. <i>Children's Health Care</i> , 1990, 19, 132-139.	0.5	160
30	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. <i>Pediatric Diabetes</i> , 2009, 10, 97-104.	1.2	160
31	Diabetes in Adolescence: Effects of Multifamily Group Intervention and Parent Simulation of Diabetes. <i>Journal of Pediatric Psychology</i> , 1989, 14, 259-275.	1.1	155
32	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 786-798.	5.5	155
33	Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial—Type 1. <i>Diabetes Care</i> , 2006, 29, 643-649.	4.3	150
34	Blood pressure, insulin, and glycemia in nondiabetic subjects. <i>American Journal of Medicine</i> , 1986, 80, 861-864.	0.6	143
35	Diabetes trends in the USA. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, S21-S26.	1.7	143
36	Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1891.	3.8	142

#	ARTICLE	IF	CITATIONS
37	Failure to Preserve $\beta$ -Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 826-832.	4.3	140
38	Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man. <i>Diabetes</i> , 2011, 60, 1-8.	0.3	140
39	DIABETIC COMPLICATIONS. <i>Endocrinology and Metabolism Clinics of North America</i> , 1996, 25, 243-254.	1.2	136
40	The artificial pancreas: current status and future prospects in the management of diabetes. <i>Annals of the New York Academy of Sciences</i> , 2014, 1311, 102-123.	1.8	131
41	complications of Diabetes Mellitus: Relationship to Metabolic Dysfunction. <i>Diabetes Care</i> , 1979, 2, 499-509.	4.3	129
42	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021, 64, 2609-2652.	2.9	128
43	Glycemic control in insulin-dependent diabetes mellitus. <i>American Journal of Medicine</i> , 1982, 72, 673-680.	0.6	121
44	Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset. <i>Diabetes</i> , 2010, 59, 679-685.	0.3	120
45	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves $\beta$ -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1917-1925.	4.3	114
46	Adolescents With Diabetes: Gender Differences in Psychosocial Functioning and Glycemic Control. <i>Children's Health Care</i> , 1995, 24, 61-78.	0.5	113
47	Home Blood Glucose Monitoring As an Aid in Diabetes Management. <i>Diabetes Care</i> , 1978, 1, 150-157.	4.3	110
48	High-dose Insulin Therapy: is it Time for U-500 Insulin?. <i>Endocrine Practice</i> , 2009, 15, 71-79.	1.1	110
49	Intensive Insulin Therapy for Treatment of Type I Diabetes. <i>Diabetes Care</i> , 1990, 13, 1265-1283.	4.3	104
50	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , 2018, 41, 1887-1894.	4.3	104
51	Diabetes Mellitus: Pathogenesis and Treatment Strategies.. <i>ChemInform</i> , 2004, 35, no.	0.1	103
52	The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2013, 36, 2615-2620.	4.3	100
53	A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial—Type 1. <i>Diabetes Care</i> , 2008, 31, 528-533.	4.3	98
54	Use of continuous glucose monitoring in children and adolescents *. <i>Pediatric Diabetes</i> , 2012, 13, 215-228.	1.2	98

#	ARTICLE	IF	CITATIONS
55	Insulin action during pregnancy. Studies with the euglycemic clamp technique. <i>Diabetes</i> , 1985, 34, 380-389.	0.3	93
56	Type 1 Diabetes TrialNet—An International Collaborative Clinical Trials Network. <i>Annals of the New York Academy of Sciences</i> , 2008, 1150, 14-24.	1.8	92
57	Effect of rituximab on human in vivo antibody immune responses. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1295-1302.e5.	1.5	91
58	Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. <i>Diabetes Care</i> , 2012, 35, 1213-1218.	4.3	84
59	Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study. <i>Diabetes Care</i> , 2015, 38, 1742-1749.	4.3	84
60	Body stature as a risk factor for diabetic sensory neuropathy. <i>American Journal of Medicine</i> , 1986, 80, 1031-1034.	0.6	82
61	Cigarette Smoking, Alcohol Use, and Physical Activity in Relation to Serum Leptin Levels in a Multiethnic Population. <i>Annals of Epidemiology</i> , 1999, 9, 108-113.	0.9	80
62	Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2007, 30, 579-585.	4.3	80
63	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. <i>Diabetes</i> , 2019, 68, 1267-1276.	0.3	80
64	Prevention and Reversal of Type 1 Diabetes—Past Challenges and Future Opportunities. <i>Diabetes Care</i> , 2015, 38, 997-1007.	4.3	79
65	HYPERINSULINEMIA AND ELEVATED BLOOD PRESSURE: CAUSE, CONFOUNDER, OR COINCIDENCE?. <i>American Journal of Epidemiology</i> , 1990, 132, 827-836.	1.6	77
66	Primary and secondary prevention of Type 1 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 161-169.	1.2	76
67	Use of Plaster Casts in the Management of Diabetic Neuropathic Foot Ulcers. <i>Diabetes Care</i> , 1986, 9, 149-152.	4.3	75
68	Novel therapies with precision mechanisms for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 364-377.	4.3	70
69	Necrobiosis lipoidica diabetorum: A clinicopathologic study. <i>Journal of the American Academy of Dermatology</i> , 1988, 18, 530-537.	0.6	69
70	Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial—Type 1. <i>Diabetes Care</i> , 2008, 31, 2188-2192.	4.3	68
71	Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial—Type 1 Participants. <i>Diabetes</i> , 2013, 62, 4179-4183.	0.3	67
72	Comparison of Methods for Blood Glucose Monitoring. <i>Diabetes Care</i> , 1981, 4, 404-406.	4.3	66

#	ARTICLE	IF	CITATIONS
73	Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. <i>Diabetes Care</i> , 1999, 22, 1092-1096.	4.3	66
74	Influence of Height on Quantitative Sensory, Nerve-Conduction, and Clinical Indices of Diabetic Peripheral Neuropathy. <i>Diabetes Care</i> , 1987, 10, 613-616.	4.3	64
75	FreeStyle <sup>®</sup> , <sup>®</sup> : A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing. <i>Diabetes Technology and Therapeutics</i> , 2000, 2, 221-229.	2.4	63
76	Increasing the Accuracy of Oral Glucose Tolerance Testing and Extending Its Application to Individuals With Normal Glucose Tolerance for the Prediction of Type 1 Diabetes: The Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2007, 30, 38-42.	4.3	61
77	Update on Worldwide Efforts to Prevent Type 1 Diabetes. <i>Annals of the New York Academy of Sciences</i> , 2008, 1150, 190-196.	1.8	61
78	Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. <i>International Journal of Clinical Practice</i> , 2010, 64, 305-315.	0.8	60
79	Optimizing Pumped Insulin Delivery. <i>Diabetes Care</i> , 1982, 5, 135-139.	4.3	59
80	Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , 2009, 32, 1603-1607.	4.3	59
81	A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History. <i>Diabetes Care</i> , 2015, 38, 271-276.	4.3	59
82	Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. <i>Diabetes Care</i> , 2010, 33, 620-625.	4.3	58
83	The Vibratory Perception Threshold in Young Diabetic Patients: Associations with Glycemia and Puberty. <i>Diabetes Care</i> , 1985, 8, 605-607.	4.3	57
84	Development of Autoantibodies in the TrialNet Natural History Study. <i>Diabetes Care</i> , 2011, 34, 1897-1901.	4.3	55
85	Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 768-771.	2.3	53
86	History of Gestational Diabetes, Insulin Resistance and Coronary Risk. <i>Journal of Diabetes and Its Complications</i> , 1999, 13, 216-223.	1.2	52
87	The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial-Type 1. <i>Diabetes</i> , 2012, 61, 1331-1337.	0.3	52
88	MICROVASCULAR COMPLICATIONS. <i>Endocrinology and Metabolism Clinics of North America</i> , 2001, 30, 833-856.	1.2	51
89	Prevention of Type 1 Diabetes: Perspectives. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 494-495.	1.8	49
90	Continuous Glucose Monitoring: An Overview of Its Development. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, S-5-S-10.	2.4	48

#	ARTICLE	IF	CITATIONS
91	Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes. <i>Diabetes Care</i> , 2010, 33, 2508-2513.	4.3	48
92	Blood Glucose Control During Pregnancy. <i>Diabetes Care</i> , 1980, 3, 69-76.	4.3	47
93	Hope vs hype: where are we in type 1 diabetes?. <i>Diabetologia</i> , 2018, 61, 509-516.	2.9	46
94	Insulin Glargine and Cancer—An Unsubstantiated Allegation. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 473-476.	2.4	43
95	PREVENTION OF TYPE 1 DIABETES. <i>Medical Clinics of North America</i> , 1998, 82, 739-755.	1.1	42
96	Validation of the Diabetes Prevention Trial—Type 1 Risk Score in the TrialNet Natural History Study. <i>Diabetes Care</i> , 2011, 34, 1785-1787.	4.3	42
97	Development of the Diabetes Health Belief Scale. <i>The Diabetes Educator</i> , 1987, 13, 292-297.	2.6	41
98	Prevention of type 1 diabetes: the time has come. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 334-343.	2.9	41
99	Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1189-1196.	4.3	41
100	HIV, Metabolic Syndrome X, Inflammation, Oxidative Stress, and Coronary Heart Disease Risk : Role of Protease Inhibitor Exposure. <i>Cardiovascular Toxicology</i> , 2004, 4, 303-316.	1.1	40
101	Self-Monitoring of Blood Glucose. <i>Medical Clinics of North America</i> , 1982, 66, 1227-1250.	1.1	38
102	Prevention of Autoimmune Diabetes and Induction of $\beta$ -Cell Proliferation in NOD Mice by Hyperbaric Oxygen Therapy. <i>Diabetes</i> , 2012, 61, 1769-1778.	0.3	38
103	Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 979-984.	4.3	37
104	Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes. <i>PLoS ONE</i> , 2011, 6, e26471.	1.1	37
105	Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. <i>Pediatric Diabetes</i> , 2015, 16, 271-279.	1.2	36
106	Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. <i>Clinical Immunology</i> , 2011, 139, 290-301.	1.4	35
107	Diabetes Mellitus and Pregnancy. <i>Diabetes Care</i> , 1978, 1, 49-63.	4.3	34
108	Cyclosporine in recent onset type I diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1992, 6, 77-88.	1.2	34

#	ARTICLE	IF	CITATIONS
109	Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population. <i>Diabetes Care</i> , 2012, 35, 1975-1980.	4.3	34
110	The Application of the Diabetes Prevention Trial—Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1552-1555.	4.3	33
111	Consequences of the COVID-19 pandemic for patients with metabolic diseases. <i>Nature Metabolism</i> , 2021, 3, 289-292.	5.1	33
112	Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial—Type 1 (DPT-1). <i>Diabetes</i> , 2010, 59, 2386-2389.	0.3	32
113	Meta-analysis of safety for low event-rate binomial trials. <i>Research Synthesis Methods</i> , 2012, 3, 30-50.	4.2	30
114	Effects of an anti-CD5 immunoconjugate (CD5-Plus) in recent onset type 1 diabetes mellitus: A preliminary investigation. <i>Journal of Diabetes and Its Complications</i> , 1993, 7, 224-232.	1.2	29
115	A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial—Type 1 (DPT-1) Participants. <i>Diabetes Care</i> , 2011, 34, 2435-2437.	4.3	29
116	Immunotherapy of Type 1 Diabetes Mellitus*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 3-9.	1.8	28
117	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. <i>Diabetes Care</i> , 2017, 40, 1494-1499.	4.3	28
118	The Importance of Self-Assessed Health in Patients with Diabetes. <i>Diabetes Care</i> , 1980, 3, 599-606.	4.3	27
119	Lessons from Studies of Insulin Pharmacokinetics. <i>Diabetes Care</i> , 1986, 9, 666-668.	4.3	27
120	An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 609-618.	2.4	27
121	The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. <i>Diabetologia</i> , 2018, 61, 84-92.	2.9	27
122	Medial plantar sensory response. <i>American Journal of Medicine</i> , 1984, 76, 842-846.	0.6	26
123	The Economic Burden of Diabetes and the Benefits of Improved Glycemic Control: The Potential Role of a Continuous Glucose Monitoring System. <i>Diabetes Technology and Therapeutics</i> , 2000, 2, 7-12.	2.4	26
124	Unexplained Hyperglycemia in Continuous Subcutaneous Insulin Infusion. <i>The Diabetes Educator</i> , 2008, 34, 327-333.	2.6	26
125	Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions. <i>Artificial Organs</i> , 2021, 45, 968-986.	1.0	24
126	Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial—Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. <i>Diabetes</i> , 2020, 69, 1827-1832.	0.3	23



#	ARTICLE	IF	CITATIONS
127	Immune intervention studies in insulin-dependent diabetes mellitus. <i>Diabetes/metabolism Reviews</i> , 1987, 3, 1017-1035.	0.2	22
128	Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: Evidence for augmentation of chimerism. <i>Transplantation Proceedings</i> , 1997, 29, 1207-1208.	0.3	22
129	Stress and immune function in diabetes mellitus. <i>Clinical Immunology and Immunopathology</i> , 1983, 27, 223-233.	2.1	21
130	Cellular Therapy for Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1599.	3.8	21
131	Safety and efficacy of inhaled human insulin (Exubera®) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial. <i>Diabetes Research and Clinical Practice</i> , 2008, 82, 238-246.	1.1	21
132	Decision-Making in Diabetes Mellitus Type 1. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, 40-50.	0.9	21
133	The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 183-187.	2.4	21
134	Biosynthetic Human Insulin: Progress and Prospects. <i>Diabetes Care</i> , 1981, 4, 140-143.	4.3	20
135	Hypertension in patients with diabetes mellitus. <i>American Journal of Hypertension</i> , 1995, 8, 100S-100S.	1.0	20
136	PROactive: A Sad Tale of Inappropriate Analysis and Unjustified Interpretation. <i>Clinical Diabetes</i> , 2006, 24, 63-65.	1.2	20
137	Central Obesity and Insulin Resistance in the Cardiometabolic Syndrome: Pathways to Preclinical Cardiovascular Structure and Function. <i>Journal of the Cardiometabolic Syndrome</i> , 2009, 4, 63-71.	1.7	20
138	Immune intervention for type 1 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2011, 65, 61-70.	0.8	20
139	Innate and adaptive immune gene expression profiles as biomarkers in human type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2012, 170, 131-138.	1.1	20
140	Home blood glucose monitoring as an aid in diabetes management. <i>Diabetes Care</i> , 1978, 1, 150-7.	4.3	20
141	Diabetic Retinopathy: A General Survey. <i>Diabetes Care</i> , 1978, 1, 127-137.	4.3	19
142	Diabetes and Exercise: Clinical Implications. <i>Diabetes Care</i> , 1979, 2, 307-311.	4.3	19
143	Human Insulin After 10 Years. <i>Diabetes Care</i> , 1993, 16, 1-3.	4.3	19
144	Insulin therapy in type II diabetes. <i>Postgraduate Medicine</i> , 1997, 101, 85-96.	0.9	19

#	ARTICLE	IF	CITATIONS
145	Cholesterol Control: Long-Term Benefit of Pancreas-Kidney Transplantation With FK 506 Immunosuppression. <i>Transplantation Proceedings</i> , 1998, 30, 513-514.	0.3	19
146	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. <i>Diabetes Care</i> , 2009, 32, e92-e93.	4.3	19
147	Challenges in developing endpoints for type 1 diabetes intervention studies. <i>Diabetes/Metabolism Research and Reviews</i> , 2009, 25, 694-704.	1.7	19
148	Instructing Patients in Making Alterations in Insulin Dosage. <i>Diabetes Care</i> , 1979, 2, 39-45.	4.3	18
149	Continuous Glucose Monitoring Symposium. <i>Diabetes Technology and Therapeutics</i> , 2000, 2, 5-5.	2.4	18
150	Performance of Technical Skills of Diabetes Management: Increased Independence After a Camp Experience. <i>Diabetes Care</i> , 1978, 1, 23-26.	4.3	17
151	Insulin Pharmacology. <i>Medical Clinics of North America</i> , 1988, 72, 1337-1354.	1.1	17
152	The Compelling Case for Anti-CD3 in Type 1 Diabetes. <i>Diabetes</i> , 2013, 62, 3656-3657.	0.3	17
153	Discovery of Phosphorylated Peripherin as a Major Humoral Autoantigen in Type 1 Diabetes Mellitus. <i>Cell Chemical Biology</i> , 2016, 23, 618-628.	2.5	17
154	The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial. <i>Diabetes Care</i> , 2018, 41, 403-409.	1.2	17
155	Continuous Subcutaneous Insulin Infusion—An Historical Perspective. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, S-5-S-9.	2.4	16
156	Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies. <i>Clinica Chimica Acta</i> , 2011, 412, 2128-2131.	0.5	16
157	The Relationship Between Maternal Glycemia and Macrosomia. <i>Diabetes Care</i> , 1980, 3, 433-434.	4.3	15
158	Splanchnic and systemic absorption of intraperitoneal insulin using a new double-tracer method. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1994, 266, E750-E759.	1.8	15
159	Glycosylated Hemoglobin: A Tool in Identifying Psychological Problems?. <i>Diabetes Care</i> , 1980, 3, 563-564.	4.3	14
160	The association between symptomatic sensory neuropathy and body stature in diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 1988, 4, 95-98.	1.1	14
161	Morning versus Bedtime Isophane Insulin in Type 2 (Non-insulin dependent) Diabetes Mellitus. <i>Diabetic Medicine</i> , 1992, 9, 826-833.	1.2	14
162	CGM—A Technology in Evolution. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 63-64.	2.4	14

#	ARTICLE	IF	CITATIONS
163	The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months. <i>Diabetes Care</i> , 2015, 38, 940-942.	4.3	14
164	The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). <i>Current Diabetes Reports</i> , 2015, 15, 49.	1.7	14
165	Foreword diabetes mellitus: Progress and directions. <i>American Journal of Medicine</i> , 1981, 70, 101-104.	0.6	13
166	Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1065-1069.	2.2	13
167	Index60 as an additional diagnostic criterion for type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 836-844.	2.9	13
168	The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. <i>Transplantation Proceedings</i> , 1995, 27, 3123-4.	0.3	13
169	Intensive Insulin Therapy: A Personal and Historical Perspective. <i>The Diabetes Educator</i> , 1989, 15, 33-39.	2.6	12
170	A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. <i>Pediatric Diabetes</i> , 2011, 12, 85-90.	1.2	12
171	Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 463-474.	2.2	12
172	Type 1 Diabetes at a Crossroads!. <i>Diabetes Care</i> , 2015, 38, 968-970.	4.3	11
173	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017, 40, 1302-1313.	4.3	11
174	Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 311-318.	4.3	11
175	Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. <i>Transplantation Proceedings</i> , 1995, 27, 3119-20.	0.3	11
176	Insulin-dependent diabetes mellitus. <i>Postgraduate Medicine</i> , 1987, 81, 163-174.	0.9	10
177	The Evolution of Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2491.	3.8	10
178	Characterizing Subgroups of Type 1 Diabetes. <i>Diabetes</i> , 2014, 63, 3578-3580.	0.3	10
179	Adaptation of $\beta$ -Cell and Endothelial Function to Carbohydrate Loading: Influence of Insulin Resistance. <i>Diabetes</i> , 2015, 64, 2550-2559.	0.3	10
180	In Response to Carter and Heinemann: Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 890-891.	1.3	10

#	ARTICLE	IF	CITATIONS
181	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1716-1723.	4.3	10
182	Neurovascular uncoupling after rapid glycemic control as a trigger of the diabetic-uremic striatopallidal syndrome. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 89-90.	1.1	9
183	The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study. <i>Diabetes Care</i> , 2020, 43, 2668-2674.	4.3	9
184	Why Control Blood Glucose? Influence on Chronic Complications of Diabetes. <i>Pediatric Annals</i> , 1987, 16, 713-724.	0.3	9
185	Insulin sensitivity and blood pressure in a biethnic sample: The Miami community health study. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 859-864.	2.4	8
186	The Year in Immune Intervention for Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, S-88-S-95.	2.4	8
187	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 206-214.	2.2	8
188	Toward Primary Prevention of Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1520.	3.8	8
189	Low-dose empagliflozin as adjunct-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 427-433.	2.2	8
190	Now Is the Time to Prevent Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 495-498.	1.8	8
191	Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team. <i>Journal of Diabetes and Its Complications</i> , 1993, 7, 224-32.	1.2	8
192	GROWTH RETARDATION IN THE LESCH-NYHAN SYNDROME. <i>European Journal of Endocrinology</i> , 1974, 75, 3-10.	1.9	7
193	Lack of Effect of Improved Glycemic Control on C-Peptide Secretion in Patients Without Residual B-Cell Function. <i>Diabetes Care</i> , 1982, 5, 334-336.	4.3	7
194	Glucose Control in Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 1997, 127, 837.	2.0	7
195	Immune therapy for treating type 1 diabetes: challenging existing paradigms. <i>Journal of Clinical Investigation</i> , 2015, 125, 94-96.	3.9	7
196	The Relation of Fasting Insulin to Blood Pressure in a Multiethnic Population: The Miami Community Health Study. <i>Annals of Epidemiology</i> , 1998, 8, 236-244.	0.9	6
197	Aberrant parasympathetic and hemodynamic function distinguishes a subgroup of psychologically distressed individuals with asymptomatic type-I diabetes mellitus. <i>International Journal of Behavioral Medicine</i> , 1999, 6, 78-94.	0.8	6
198	Modeling Preclinical Cardiovascular Risk for Use in Epidemiologic Studies: Miami Community Health Study. <i>American Journal of Epidemiology</i> , 2001, 154, 765-776.	1.6	6

#	ARTICLE	IF	CITATIONS
199	Pulmonary Insulin Delivery—State of the Art 2007. <i>Diabetes Technology and Therapeutics</i> , 2007, 9, S-1-S-3.	2.4	6
200	Immunomodulation for type 1 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2010, 64, 59-63.	0.8	6
201	George S. Eisenbarth: Insulin and Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 1437-1442.	4.3	6
202	Progress towards a bionic pancreas. <i>Nature Reviews Endocrinology</i> , 2015, 11, 75-76.	4.3	6
203	A plethora of insulins. <i>Diabetes Care</i> , 1980, 3, 638-9.	4.3	6
204	Effect of Cyproheptadine Administration on Insulin Secretion in Acromegalic, Diabetic and Normal Subjects. <i>Hormone and Metabolic Research</i> , 1975, 7, 279-283.	0.7	5
205	The Spectrum of Insulin Resistance. <i>Diabetes Care</i> , 1979, 2, 319-322.	4.3	5
206	Effect of cyclosporine a on serum tumor necrosis factor $\hat{\pm}$ in new-onset type I (insulin-dependent) diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1994, 8, 40-44.	1.2	5
207	TACTICS FOR TYPE I DIABETES. <i>Endocrinology and Metabolism Clinics of North America</i> , 1997, 26, 647-657.	1.2	5
208	Immunotherapy Trials for Type 1 Diabetes: The Contribution of George Eisenbarth. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, S2-13-S2-20.	2.4	5
209	Struggles With Clinical Translation of Immune Intervention Trials. <i>Diabetes Care</i> , 2014, 37, 1173-1175.	4.3	5
210	Imagining a better future for all people with type 1 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2019, 15, 623-624.	4.3	5
211	Weekly Insulin Becoming a Reality. <i>Diabetes Care</i> , 2021, 44, 1459-1461.	4.3	5
212	Etiology and Pathogenesis of Insulin Dependent Diabetes Mellitus. <i>Pediatric Annals</i> , 1987, 16, 682-692.	0.3	5
213	Psychological issues in diabetes. <i>Diabetes Care</i> , 1981, 4, 656-7.	4.3	5
214	Pulmonary Insulin Update. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 834-839.	2.4	4
215	Brief Commentary: Confusing Treatment Guidelines for Patients With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2018, 169, 253.	2.0	4
216	Counterregulatory Hormones, Rebound Hyperglycemia, and Diabetic Control. <i>Diabetes Care</i> , 1979, 2, 526-529.	4.3	3

#	ARTICLE	IF	CITATIONS
217	The effect of ejaculation on albumin excretion rate. <i>Journal of Diabetes and Its Complications</i> , 1992, 6, 163-165.	1.2	3
218	Glycemia and cardiovascular diseases in type 2 diabetes. <i>Journal of Internal Medicine</i> , 2010, 268, 468-470.	2.7	3
219	Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes. <i>Pediatric Diabetes</i> , 2019, 20, 408-413.	1.2	3
220	Evidence for Glycated Hemoglobin Targets from the Diabetes Control and Complications Trial. <i>Endocrine Practice</i> , 2002, 8, 27-30.	1.1	3
221	"Control" and diabetic complications. <i>Diabetes Care</i> , 1978, 1, 204-5.	4.3	3
222	Type I diabetes . . . regimens, targets, and caveats. <i>Diabetes Care</i> , 1982, 5, 547-52.	4.3	3
223	The Winds of Change. <i>Diabetes</i> , 1993, 42, 637-642.	0.3	2
224	Resting parasympathetic status and cardiovascular response to orthostatic and behavioral challenges in type I insulin-dependent diabetes mellitus. <i>International Journal of Behavioral Medicine</i> , 1994, 1, 137-162.	0.8	2
225	Thirty Years of Diabetes Care: Reflections on the Beginning. <i>Diabetes Care</i> , 2008, 31, 183-184.	4.3	2
226	Type 1 Diabetes. , 2012, , 65-94.		2
227	Immune Intervention for Type 1 Diabetes, 2013-2014. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, S-80-S-87.	2.4	2
228	Prevention of Type 1 Diabetes. <i>Endocrinology</i> , 2018, , 1-13.	0.1	2
229	Corona Pandemic: Assisted Isolation and Care to Protect Vulnerable Populations May Allow Us to Shorten the Universal Lock-Down and Gradually Re-open Society. <i>Frontiers in Public Health</i> , 2020, 8, 562901.	1.3	2
230	New insights into halting type 1 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 475-476.	5.5	2
231	Dietary Planning in Insulin-Dependent Diabetes Mellitus. <i>Pediatric Annals</i> , 1983, 12, 652-657.	0.3	2
232	Diabetes Mellitus: Pathogenesis and Natural History. , 2004, , 11-27.		2
233	Simplifying the diagnosis of diabetes mellitus. <i>American Family Physician</i> , 1998, 58, 1290-2.	0.1	2
234	Thoughts Along the Way. <i>Diabetes Care</i> , 1979, 2, 58-59.	4.3	1

#	ARTICLE	IF	CITATIONS
235	The Flashlight Test Lacks Validity as a Screen for Nocturnal Hypoglycemia. <i>Diabetes Care</i> , 1984, 7, 269-272.	4.3	1
236	The association between heart rate and glycemia in adult diabetic subjects. <i>Diabetes Research and Clinical Practice</i> , 1988, 5, 25-29.	1.1	1
237	SSCI Presidential Address: Challenges of the Future. <i>American Journal of the Medical Sciences</i> , 1993, 306, 5-9.	0.4	1
238	Combined Octreotide and Insulin Therapy in Acromegaly. <i>Endocrine Practice</i> , 1997, 3, 19-21.	1.1	1
239	New Diabetes Criteria and Clinical Implications. <i>Drugs</i> , 1999, 58, 1-2.	4.9	1
240	Type 1 diabetes mellitus: immune intervention. <i>International Journal of Clinical Practice</i> , 2012, 66, 56-61.	0.8	1
241	New medications for the treatment of diabetes. <i>International Journal of Clinical Practice</i> , 2012, 66, 85-93.	0.8	1
242	Immune Intervention for Type 1 Diabetes, 2012â€“2013. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, S-85-S-91.	2.4	1
243	Sleeping oxygen saturation, rapid eye movement sleep, and the adaptation of postprandial metabolic function in insulin sensitive and resistant individuals without diabetes. <i>Physiology and Behavior</i> , 2018, 191, 123-130.	1.0	1
244	Bringing closure: towards achieving a better understanding of Israel. <i>Lancet, The</i> , 2019, 394, 559.	6.3	1
245	A Wake-Up Call. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 66-66.	2.4	1
246	Type II diabetes: toward improved understanding and rational therapy. <i>Diabetes Care</i> , 1982, 5, 447-50.	4.3	1
247	Targeted glycemic control in type 2 diabetes. <i>The Journal of the Florida Medical Association</i> , 1998, 85, 7-15.	0.0	1
248	Association of HLA-DQ Heterodimer Residues $\hat{\sim}18\hat{I}^2$ and $\hat{I}^257$ With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trialâ€™Type 1. <i>Diabetes Care</i> , 2022, 45, 1610-1620.	4.3	1
249	An Algebra for Adiposity?. <i>Diabetes Care</i> , 1981, 4, 328-329.	4.3	0
250	Introduction: Symposium on immunology and diabetes. <i>Diabetes/metabolism Reviews</i> , 1987, 3, 723-724.	0.2	0
251	Symposium on immunology and diabetes continued comments on part 2. <i>Diabetes/metabolism Reviews</i> , 1987, 3, 857-858.	0.2	0
252	Prevention of Type 1 Diabetes. , 0, , 43-68.		0

#	ARTICLE	IF	CITATIONS
253	Latent autoimmune diabetes in adults: the search for interventions continues. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 600-601.	2.9	0
254	DIABETES MELLITUS: OLD ASSUMPTIONS AND NEW REALITIES. , 2008, , 23-32.		0
255	Management of Type 1 Diabetes. , 2012, , 95-113.		0
256	ATG in type 1 diabetes: an unanswered question. Lancet Diabetes and Endocrinology,the, 2013, 1, 265-266.	5.5	0
257	Defeating diabetes. Diabetes Management, 2014, 4, 473-477.	0.5	0
258	Harold E. Lebovitz, MD: Legendary Diabetologist. Diabetes Care, 2016, 39, 2118-2121.	4.3	0
259	Prevention of Type 1 Diabetes. Endocrinology, 2018, , 451-463.	0.1	0
260	The UGDP and insulin therapy. Diabetes Care, 1978, 1, 328-9.	4.3	0
261	Lipids, diet, diabetes, and atherogenesis. Diabetes Care, 1978, 1, 138-9.	4.3	0
262	Sulfonylurea drugs 1978. Diabetes Care, 1978, 1, 205-6.	4.3	0
263	Screening for diabetes mellitus. The Journal of the Florida Medical Association, 1985, 72, 1033-7.	0.0	0
264	Carolinas' camp for diabetic children. I. Report of first five years of operation. North Carolina Medical Journal, 1973, 34, 935-8.	0.1	0
265	Evidence, implications, and corollaries. Diabetes Care, 1981, 4, 573-5, 1214.	4.3	0
266	Upgrading diabetes therapy. Now that we know it matters. The Journal of the Florida Medical Association, 1994, 81, 599-602.	0.0	0
267	Combined kidney/pancreas transplantation in diabetes mellitus. The Journal of the Florida Medical Association, 1994, 81, 339-43.	0.0	0
268	Control of diabetes during pregnancy: 1985. JAMA - Journal of the American Medical Association, 1986, 255, 647-648.	3.8	0